From preclinical promise toward the clinic
Our lead program, SymphNode, is in preclinical development for solid tumors. Active programs and potential future applications are shown separately below.
Development pipeline
Solid bars show programs in active development. Dashed bars show potential applications of the platform that are not yet in active development.
Lead program status
Preclinical evidence
Promising antitumor activity in preclinical cancer models, including evidence of improved survival and reduced metastatic tumor growth.
Current work
Advancing preclinical evaluation, safety testing, and manufacturing development to support future clinical translation.
Non-dilutive support
Funded by the NIH’s National Cancer Institute through a Fast-Track Phase II SBIR award.
Investigational technology. SymphNode remains investigational and is not an approved cancer treatment. It has not been evaluated in human clinical trials, and its safety and efficacy have not been established.